Skip to main content
. Author manuscript; available in PMC: 2017 Jan 24.
Published in final edited form as: J Nucl Med. 2016 Feb 23;57(6):981–988. doi: 10.2967/jnumed.115.167932

Figure 2.

Figure 2

Evaluation of 89Zr-ACKR3-mAb in vitro and optimization of its specific activity in vivo. ACKR3 cell-surface expression by flow cytometry illustrated by overlapping histograms and mean fluorescence intensity (MFI) (A); in vitro binding assay with 89Zr-ACKR3-mAb (B); internalization assay in 231-ACKR3 cells (C); optimization of 89Zr-ACKR3-mAb specific activity using ex vivo biodistribution; organs from NOG mice bearing 231/231-ACKR3 tumors were harvested 48hrs post injection of 1.5MBq (40µCi) of 89Zr-ACKR3-mAb accompanying 10, 30, 70 or 100µg of non-labeled ACKR3-mAb (D); 231-ACKR3 represents MDA-MB-231-ACKR3; 231 represents MDA-MB-231; 231-CXCR4 represents MDA-MB-231-CXCR4; p ≤ 0.05 (*), ≤ 0.0001 (****).